In this issue:
HSCT for the treatment of MM
NDMM patients in CR have improved survival rates by treatment with ASCT and lenalidomide maintenance
Once vs. twice weekly carfilzomib in patients with RRMS
AEs of novel agents in MM
Multiple large focal lesions are a prognostic factor in MM
Suppression of focal lesions on PET-CT in NDMM
BTZ maintenance therapy is not adequate for MM patients who plateaued after BTZ-based induction therapy
QoL in MM patients
Impact of immunoparesis on survival in NDMM
Tofacitinib as an anti-myeloma therapeutic
Please login below to download this issue (PDF)